Anti-GM1 Antibodies Do Not Predict Positive Response to IVIG in Lower Motor Neur
Anti-GM1 Antibodies Do Not Predict Positive Response to IVIG in Lower Motor Neuron Disease
Source: van den Berg LH, et al. Intravenous immunoglobulin treatment in lower motor neuron disease associated with highly raised anti-GM1 antibodies. J Neurol Neurosurg Psychiatry 1997;63:674-677.
Multifocal motor neuropathy with conduction block and distal lower motor neuron syndrome with high-titer serum IgM anti-GM1 antibodies respond to immunosuppressive treatment modalities including plasma exchange and cyclophosphamide (Pestronk A, et al. Ann Neurol 1988;24:73-78; Pestronk A, et al. Neurology 1994;44:2027-2031). Intravenous immunoglobulin (IVIG) is similarly beneficial in the former but not, it would appear, in the latter. Five patients with lower motor neuron disease and raised serum anti-GM1 antibodies, but without evidence of conduction block on nerve conduction studies, received 0.4 g/kg IVIG for five consecutive days in an open-label study. One patient alone responded, and this was confirmed in a subsequent double-blind, placebo-controlled study. Sadly, despite continued treatment, muscle strength deteriorated within six months to below pre-treatment levels. IVIG appears to be ineffective for purely lower motor neuron syndromes in the absence of conduction block, and the presence of high titer anti-GM1 antibodies does not alter responsivity. mr
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.